Question 1

Are peptides legal?

Accepted Answer

Peptides are not illegal as a class — but whether a specific product is legal depends on what it is, who is selling it, and how it is marketed. FDA-approved peptide drugs (semaglutide, tirzepatide, insulin) are legal prescription drugs. Compounded peptides are lawful only through the narrow 503A/503B pharmacy framework. Genuine research supply sold to qualified researchers sits in a lawful research channel. Unapproved injectables sold online to consumers — even under "research use only" labels — are unapproved new drugs as sold: on August 24, 2026 the FDA warned five online sellers on exactly that basis. None of the wellness peptides commonly marketed for recovery, weight loss, or longevity (BPC-157, TB-500, KPV, MOTS-c) is FDA-approved or lawfully compoundable today. See the FDA warning-letter explainer, the enforcement timeline, and the retatrutide legality explainer.

Question 2

Are peptides safe?

Accepted Answer

Some are; many marketed ones are not proven. Insulin and semaglutide — the molecule behind Ozempic and Wegovy — are FDA-approved peptides with years of human safety data. The peptides sold for recovery, anti-aging and longevity are not FDA-approved, and a September 2026 UCLA Health review of six popular peptide supplements — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu — concluded that all six "cannot be recommended" for musculoskeletal recovery: more than two-thirds of the studies the team analyzed were animal studies, human evidence for the marketed uses was weak or absent, and no long-term safety data exist. FDA has also placed some peptides on its Category 2 list of bulk drug substances that "may present significant safety risks" for compounding, and its own scientists found insufficient human safety data. Safety depends on the specific peptide, the evidence behind it, and who made it. See UCLA Health's review: UCLA Health reviewed 6 peptides: the evidence, and our explainer: Peptides are having a moment: what the ads don't tell you.

Question 3

Are peptides FDA approved?

Accepted Answer

Some are. Insulin and GLP-1 drugs like semaglutide and tirzepatide are FDA-approved peptides that underwent years of testing. None of the wellness peptides commonly marketed for recovery, weight loss or longevity — BPC-157, TB-500, KPV, MOTS-c, GHK-Cu, ipamorelin — is FDA-approved. An FDA advisory committee's July 2026 vote recommending that some become eligible for pharmacy compounding is not approval, and FDA staff opposed the recommendation. The five sellers warned on August 24, 2026 offered "illegal variations" of semaglutide and tirzepatide plus unapproved copies of retatrutide, tesamorelin, elamipretide, and bremelanotide — products the FDA classified as unapproved new drugs as sold. See FDA's bulk drug substances page and our explainer on the September letters.

Question 4

Are research peptides legal?

Accepted Answer

A genuine research channel exists — laboratory supply sold to qualified researchers without consumer-facing therapeutic claims. What the August 24, 2026 FDA warning letters mark unlawful is the consumer "research peptide" trade: websites selling injectables with dosing calculators, reconstitution water, and product pages describing human use, under "research use only" labels. The FDA rejected the disclaimer, finding that "evidence obtained from your website establishes that your products are intended to be drugs for human use." Enforcement targets sellers, but the buyer's risk is a product with no FDA review of safety, quality, or effectiveness. See the FDA warning-letter explainer and our gray-market analysis.

Question 5

What is Category 2 / the no-compounding list?

Accepted Answer

Category 2 is the FDA's interim-policy designation for bulk drug substances that "may present significant safety risks" and receive no compounding enforcement discretion under sections 503A and 503B of the FD&C Act. As of the FDA's April 22, 2026 list, the peptides still in Category 2 are GHRP-2, GHRP-6, ipamorelin acetate (503B), and kisspeptin-10 (503A). "No-compounding list" is colloquial shorthand — no FDA document carries that title. BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon are not currently Category 2: their nominations were withdrawn in 2026, a procedural step that does not make them legal to compound. The GLP-1 track is separate: an April 2026 FDA proposal would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, and the Fifth Circuit's August 2026 ruling affirmed delistings that ended bulk GLP-1 compounding. See the FDA Category 2 page, the FDA timeline, and our 503A/503B docket map.

Question 6

What does FDA Category 2 mean for peptides?

Accepted Answer

Category 2 is FDA's screening designation for bulk drug substances that "may present significant safety risks" when used in compounding under sections 503A/503B of the FD&C Act. It is not a formal ban, not an approval decision, and not a compounding authorization — it flags substances with safety concerns FDA believes warrant attention. FDA added four peptides to Category 2 in September 2023 — GHRP-2, GHRP-6, ipamorelin acetate, and kisspeptin-10 — and they remain listed. BPC-157 and TB-500, which were also evaluated under Category 2, are no longer on it: their nominations were withdrawn in 2026, which removed the safety-risk flag but changed nothing else. They are not banned, not approved, not on the list pharmacies may compound, and still without an approved application. The August 24, 2026 warning letters are a separate enforcement track aimed at sellers of finished injectables, not at compounders. See the FDA Category 2 page and the FDA timeline.

Question 7

What does an FDA warning letter mean?

Accepted Answer

An FDA warning letter is the agency's notice of significant violations and a demand for correction — not a conviction, a fine, a recall, or a court order. The five letters issued August 24, 2026 and posted September 1 give the sellers 15 business days to respond and warn that failure to "adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction." A warned seller is not FDA-cleared: the letters are public records, and the FDA explicitly says they are "not intended to be an all-inclusive list of the violations that may exist." See what the crackdown means for buyers.

Question 8

Is BPC-157 FDA approved?

Accepted Answer

No. BPC-157 is not FDA-approved for any use. An FDA advisory committee voted in July 2026 to recommend BPC-157 for the 503A compounding bulks list (for ulcerative colitis), but a committee recommendation is not approval, FDA's own scientists opposed it, and any change would require a proposed rule, public comment and final rule — a process that would take at least a year. Nothing legally changed for consumers after the vote, and BPC-157 was not among the products named in the August 24, 2026 warning letters; the letters targeted GLP-1s, tesamorelin, elamipretide, and bremelanotide sold by five online vendors. The enforcement wave is context for BPC-157's sellers, not a change to BPC-157's status. See the FDA BPC-157 briefing, our BPC-157 page, and the warning-letter explainer.

Question 9

Is BPC-157 safe?

Accepted Answer

The honest answer is unknown — and that is the risk. FDA's July 2026 briefing document concluded there is "insufficient clinical safety information to characterize the safety profile" of BPC-157 and found no studies administering it to humans by the routes people actually use (oral, subcutaneous, nasal, transdermal). FDA also cited immunogenicity risk and peptide-related impurity concerns. FDA staff recommended against adding it to the compounding bulks list; the advisory committee voted 8-6 (one abstention) to recommend it, but that is not approval and not a rule. BPC-157 is not FDA-approved and sits in a gray zone after its nomination was withdrawn. See also the FDA Category 2 page and the BPC-157 compound page.

Question 10

Is TB-500 safe?

Accepted Answer

No peer-reviewed human trials of TB-500 for musculoskeletal use exist, so its long-term safety in humans is unknown. FDA has identified no human exposure data for the TB-500 fragment — its Category 2 entry states: "FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment." A September 2026 UCLA Health review of six popular peptide supplements reached the same verdict: no peer-reviewed human trials of TB-500 for musculoskeletal use, animal data only on the related protein thymosin beta-4 (not marketed TB-500), a human record limited to the 2016 Essendon AFL doping case (34 players banned, no documented performance benefits), and WADA-prohibited status. UCLA's verdict: TB-500 "cannot be recommended." TB-500's nomination was withdrawn from Category 2 in 2026, which removed the safety-risk flag but changed nothing else — it is still not approved and not on the compounding list. See the FDA Category 2 page, the TB-500 compound page, and UCLA Health's review: UCLA Health reviewed 6 peptides: the evidence.

Question 11

What happened at the July 2026 FDA advisory committee vote on peptides?

Accepted Answer

At its July 23-24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides — BPC-157, KPV, TB-500, MOTS-c, Emideltide, Epitalon and Semax. It voted 8-6 with one abstention to recommend BPC-157 (for ulcerative colitis) and KPV (for wound treatment and inflammatory conditions) for the 503A bulks list, and recommended six of the seven overall. FDA staff had recommended against all seven, citing insufficient evidence. The vote does not change any product's legal status: a recommendation still must become a proposed rule, survive public comment, and become a final rule, and press reports describe the outcome as a step toward possible eligibility, not approval. See the FDA PCAC overview, our July PCAC tracker, and the 503A/503B docket map.

Question 12

Is a recommendation to allow compounding the same as FDA approval?

Accepted Answer

No — this is the most common confusion in peptide marketing. A PCAC recommendation is advisory. FDA does not have to follow it, and its own scientists recommended against it. Any change runs through notice-and-comment rulemaking: a proposed rule, a public comment period and a final rule, which would likely take at least a year. Compounding eligibility is also separate from approval — a substance can be allowed for compounding without ever being approved as a drug. None of the wellness peptides is an FDA-approved medicine, and none of the six recommended in July 2026 is lawfully compoundable today. See the FDA Category 2 page.

Question 13

What is the difference between FDA-approved peptides (like Ozempic) and wellness peptides (like BPC-157)?

Accepted Answer

Approved peptides such as insulin and semaglutide went through clinical trials establishing safety and effectiveness for specific uses, and FDA judged the benefits to outweigh the risks for those uses — approval does not mean side-effect-free, and it does not mean a drug works for every use it is marketed for. Does Ozempic slow aging? Not proven in humans. A September 2, 2026 NIH-funded study published in Nature, announced the same day in an NIH news release, found that starting semaglutide late in life extended lifespan in older healthy female mice and tempered hallmarks of aging, with benefits beyond calorie restriction alone — but it was a mouse study, in female mice only, and it does not prove the same effect in humans. Aging is not an FDA-recognized indication for Ozempic, Wegovy, or any GLP-1 drug; see also Are peptides FDA approved? Read our explainer: Semaglutide lifespan mouse study: what Nature found. In September 2026, two studies also looked at hair loss with GLP-1 drugs such as Ozempic, Wegovy and Zepbound. NYU Langone (Journal of Investigative Dermatology) reported about a 7 percent added risk of hair loss in men whose genetics already predispose them to male-pattern hair loss — the first reported genetic link. Penn Medicine (BMJ) found GLP-1 use in people with type 2 diabetes was linked to increased hair-loss risk versus two other diabetes drug classes, but the absolute risk was low — a real but muted signal, mostly the temporary, non-scarring shedding type. These studies show association, not proven direct causation; neither advises stopping a prescribed medication, and anyone noticing hair loss should talk to their clinician. Wellness peptides such as BPC-157, TB-500, KPV and MOTS-c have not gone through that process at all: most were never studied in humans for the uses they are marketed for — recovery, longevity, fat loss — and FDA has flagged immunogenicity, impurity and characterization concerns. Some have promising preclinical research and may eventually earn approval, but "some peptides are effective medicines" does not mean "all peptides are." See Peptides are having a moment and our explainer on the studies: GLP-1 and hair loss: what the 2026 NYU and Penn studies found.

Question 14

Why do peptide products say "research use only"?

Accepted Answer

"Research use only" is legal positioning, not a safety warning. It lets a seller avoid marketing the product as a drug intended for human use — which would require FDA approval — while still selling peptide powder to people who inject it. The August 24, 2026 FDA letters show the limits of that label: the agency found the sellers' own websites — dosing calculators, reconstitution water, product pages describing human effects — established that the products were "intended to be drugs for human use." The label says nothing about purity, sterility, or whether the substance is safe. Forensic testing of common illicit peptide products has found arsenic and lead, in some samples at up to ten times the injectable toxicity limit, with purity swinging from roughly 5% to 75%. That label does not protect you. See Peptides are having a moment.

Question 15

Is buying peptides online safe?

Accepted Answer

No — not for unapproved injectable peptides bought for human use. The products sold by the five sellers warned on August 24, 2026 have no FDA review of safety, effectiveness, or quality, and the FDA warned that injectable drugs "can pose risks of serious harm to users" because they are delivered directly into the body and bypass key defenses against toxins and microorganisms. Legitimate online purchases run through a U.S.-licensed pharmacy that requires a prescription — the FDA's BeSafeRx standard — not a research-vendor website. PeptidesBeat has documented contaminated products with severe outcomes, counterfeit retatrutide tied to liver-toxicity reports, and major dose inaccuracy in black-market vials. See what the FDA letters say about the online market. A 2026 case report documents a hospital presentation after an online-sourced product marketed as retatrutide in a patient with type 1 diabetes, confounded by a concurrent bacterial infection.

Question 16

How do I verify a legitimate source?

Accepted Answer

Use the FDA's BeSafeRx checks: the seller must be licensed in the U.S. and by your state board of pharmacy — "If your online pharmacy is not listed, you should not use that pharmacy" — require a doctor's prescription, have a licensed pharmacist available to answer questions, provide a U.S. physical address and phone number, send product that matches what your usual pharmacy dispenses, and avoid "too good to be true" prices. The five sellers warned August 24, 2026 fail nearly every check: none is a licensed pharmacy, none requires a prescription, and their own labels said the products were not for human use. There is no legitimate version of buying an unapproved injectable peptide online for human use. See the FDA consumer update and our compounding pharmacy checklist.

Question 17

How can I spot exaggerated peptide marketing claims?

Accepted Answer

Ask whether the claim matches the evidence and the regulatory record. Red flags: "research use only" fine print (legal positioning, not a safety warning); influencer discount codes (5-30% commissions that fund the promotion); claims that a peptide is "FDA approved" when it is not; and ads describing uses FDA never reviewed — BPC-157 was reviewed for ulcerative colitis and TB-500 for wound healing, not tendon recovery or longevity. Ask the six consumer questions: Is there a good reason to take this? What is its legal status? What evidence supports the claim? What is known about safety by dose and route? What is in the vial, and who tested it? Is there an approved alternative? See Peptides are having a moment for the full walkthrough.

Question 18

Can I legally buy peptides online or from a med spa?

Accepted Answer

Legality depends on the substance, the state, and the seller — and legal is not the same as safe. FDA-approved peptides are prescription drugs and legally require a prescription. The wellness peptides (BPC-157, TB-500, KPV and the rest) are not approved, are not on FDA's compounding list, and the FDA's August 24, 2026 warning letters put web sellers of unapproved injectables on notice that "research use only" labeling does not shield them from enforcement. A prescription from a licensed provider for a compounded product may be legal in your state, but "research use only" powder bought online from a vendor that is not a licensed pharmacy is not a regulated medicine. Ask the provider for the specific product's regulatory status and testing documentation. See the FDA Category 2 page.

Question 19

Do doctors recommend peptides?

Accepted Answer

Not for the wellness peptides sold online. The named clinicians and health systems that addressed these products in September 2026 said the human evidence is not there yet: MedPage Today's Dr. Mike Varshavski (Mikhail Varshavski, DO) built his September 11, 2026 explainer around needing more evidence; MSK oncologist Dr. Larry Norton said "until these products are properly studied, the risks are too great to ignore"; and UCLA Health's September 2026 review of six popular peptides concluded all six "cannot be recommended." FDA-approved peptide drugs are the exception — insulin, semaglutide and tirzepatide are prescribed and monitored by clinicians, and that is not the same as a doctor recommending an unapproved peptide.

Peptide Legality, Safety, and FDA Regulatory FAQ

Legality and FDA status